A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
Price : $35 *
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2016 Number of treatment arms changed from 2 to 1. Study design was changed from randomized to non-randomized, parallel to single-group assessment.
- 05 Oct 2016 Planned number of patients changed from 100 to 60.